CagriSema-treated patients achieved superior weight loss compared with those who received cagrilintide 2.4mg, semaglutide 2.4mg or placebo. Topline data were announced from a phase 3 trial ...

In a phase 3 clinical trial investigating the usefulness of its anti-obesity drug candidate CagriSema, after being injected weekly for 68 weeks, patients lost 22.7% of their weight on average.

disappointing trial results of Novo Nordisk's experimental CagriSema weight loss drug, and more. Elon Musk’s Go-To Cost-Cutter Is Working for DOGE I've been to all 50 states. I'm not in a rush ...

Novo Nordisk NVO has achieved the primary endpoint in a late-stage study evaluating its next-gen subcutaneous obesity treatment candidate, CagriSema. The results showed that treatment with the ...

On Monday, KeyBanc provided insights into the impact of Novo Nordisk (NYSE:NVO)'s Phase 3 results for its obesity treatment, CagriSema, on the GLP-1 market. The analysis suggests that the potential of ...

Investing.com -- Novo Nordisk (CSE:NOVOb) shares jumped over 9% on Monday, despite the company’s disappointing results for its experimental obesity treatment, CagriSema. This followed the release of ...

Novo Nordisk has announced its latest trial result for the new obesity drug, CagriSema, which disappointed investors and sent its share price plunging 20% in Denmark on Friday, the sharpest one ...

Investing.com -- Novo Nordisk (CSE:NOVOb) shares jumped over 9% on Monday, despite the company’s disappointing results for its experimental obesity treatment, CagriSema. This followed the ...

The experimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7 percent in a late-stage trial, Reuters quoted Novo Nordisk as saying on Friday ...